Ovarian Cancer Doctors Abroad — Page 3

Professor Saban Sec leads the medical oncology team at Valued Med Hub Hospitals, focusing on urogenital and rare tumours. He serves as a representative for the Turkish Medical Oncology Association, helping set national standards for patient care.

• Specialises in urogenital cancers, managing complex malignancies of the reproductive system
• Expert in rare tumour treatments, providing options for hard-to-treat cases
• Researches genetic markers and mutation profiles to tailor specific drug therapies
• Member of the Turkish Medical Oncology Association and Istanbul Medical Chamber

Professor Ozcan Yildiz is a leading medical oncologist at Medipol Mega University Hospital with a deep academic background in treating complex gynaecological cancers.

• Specialises in managing dysgerminoma and gestational choriocarcinoma using targeted medical protocols
• Expert in treating metastatic neuroectodermal ovarian tumours, particularly in high-risk obstetric cases
• Focuses on managing hormonal complications and hypoadrenalism during endometrial and ovarian cancer treatment
• Published extensive research on paraneoplastic syndromes to improve patient safety during chemotherapy

The doctor is an oncologist specializing in the treatment of breast, lung, and gastrointestinal cancers. Currently, the doctor practices at Istinye Liv University Hospital.

With a career spanning multiple esteemed institutions, the doctor has served as an Internal Medicine Specialist at Malatya State Hospital, a physician at Ankara Oncology Clinic, and a member of the Oncology Department at Erzurum Regional Training and Research Hospital.

The doctor graduated from the Faculty of Medicine at Selcuk University and achieved the title of Associate Professor in 2016.

Education & Expertise

• 1998 to 2004 – Istanbul University, Istanbul Faculty of Medicine
• 2005 to 2009 – Düzce University, Internal Medicine Specialization
• 2009 to 2010 – Beytüşşebap State Hospital, Compulsory Internal Medicine Service
• 2010 to 2013 – Bülent Ecevit University, Medical Oncology Specialization
• 2013 to 2015 – Recep Tayyip Erdoğan University, Medical Oncology Compulsory Service
• 2015 to Present – Associate Professor, Recep Tayyip Erdoğan University
• 2015 to 2021 – Lecturer, Medical Oncology, Sakarya University Faculty of Medicine
• 2020 to Present – Professor, Sakarya University Faculty of Medicine
• 2020 to Present – Ph.D. Student, Inorganic Chemistry, Sakarya University

Experience

• 2008 – Cleveland Clinic, Rheumatology & Gastroenterology Rotation
• 2016 to 2017 – Northeastern University, The Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, U.S.

Professional Memberships

• TTOD (Turkish Society of Medical Oncology)
• ASCO (American Society of Clinical Oncology)
• ESMO (European Society for Medical Oncology)

Professor Mustafa Serkan Alemdar is a medical oncology specialist at Medical Park Antalya with deep roots in university-level clinical research.

• Specialises in medical oncology for managing ovarian malignancies and complex solid tumours
• Trained at Akdeniz University – a prominent Turkish centre for medical research
• Provides systemic therapies including targeted treatments designed to attack specific cancer cells
• Focuses on evidence-based protocols to manage disease progression and improve patient outcomes
• Coordinates care within a multidisciplinary team at Medical Park's oncology department

Assoc. Prof. Atakan Topçu, M.D., is a medical oncologist at Medipol University and Medipol Acıbadem Regional Hospital. He treats solid tumors, including lung, breast, colorectal, gastric, and neuroendocrine cancers. His work also covers targeted therapies, immunotherapy, geriatric oncology, and cancer-related malnutrition, cachexia, and sarcopenia.

He has authored more than 50 peer-reviewed papers. Recent work includes a 2024 Frontiers in Medicine study on geriatric syndromes and a 2023 Future Oncology paper on sarcopenia and anxiety in lung cancer. He has also published on the CONUT score in breast cancer and on malnutrition in HER2-negative metastatic gastric cancer.

Dr. Topçu serves on the Editorial Board of BMC Cancer. He is a member of the Turkish Society of Medical Oncology, ESMO, and the Turkish Geriatrics Society. Education and training: M.D., Uludağ University; residency in Internal Medicine, Marmara University; fellowship in Medical Oncology, Bezmialem Vakıf University.

Associate Professor Nail Paksoy is a board-certified medical oncologist specialising in drug-resistant and advanced ovarian cancer cases at Medipol Bahçelievler University Hospital.

• ESMO board-certified specialist with expert knowledge in European cancer treatment protocols
• Specialises in carboplatin desensitisation – a technique that allows patients to safely continue vital chemotherapy despite allergic reactions
• Serves as a sub-investigator for international clinical trials, including the use of Olaparib for advanced ovarian cancer
• Researches hemogram parameters to better predict patient outcomes and survival in late-stage ovarian carcinoma

Dr. Irfan Cicin is a Professor of Medical Oncology at the Trakya University Faculty of Medicine (2015–present). He has over 20 years of medical oncology experience and has held academic roles since 2010.

Education: MD, Istanbul University – Cerrahpaşa (1991–1997). Residency in Internal Medicine, Trakya University (1997–2002). Fellowship in Medical Oncology, Trakya University (2002–2004).

Practice: Medical Oncologist, Trakya University (2005–2008). Medical Oncologist, Elazığ Training and Research Hospital (2008–2010). Associate Professor of Medical Oncology, Trakya University (2010–2015). He previously served as a physician in the Turkish Air Force at Etimesgut Military Hospital (2004–2005).

Professor Ercan Ozden is a medical oncology specialist at VM Medical Park Pendik Hospital with deep roots in Istanbul's top medical institutions.

• Specialises in medical oncology at Kocaeli University – a leading research and teaching hospital
• Trained in internal medicine at Istanbul University Cerrahpasa School of Medicine
• Focuses on systemic treatments for advanced-stage ovarian cancer cases
• Expertise includes targeted therapies and chemotherapy protocols